Profile data is unavailable for this security.
About the company
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Manufacturing segment. Its geographical segments include India, the United States, Europe, and Rest of the world. In India, the Company sells bulk drugs and intermediates, fine chemicals & services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s subsidiaries are Suven Pharma Inc. and Casper Pharma Private Limited.
- Revenue in INR (TTM)9.34bn
- Net income in INR2.40bn
- Incorporated2018
- Employees1.05k
- LocationSuven Pharmaceuticals LtdSDE Serene ChambersRoad no. 5, Avenue 7, Banjara hillsHYDERABAD 500081IndiaIND
- Phone+91 4 023549414
- Fax+91 4 023541152
- Websitehttps://www.suvenpharm.com/
Mergers & acquisitions
Acquired company | SUVENPHAR:NSI since announced | Transaction value |
---|---|---|
Cohance Lifesciences Ltd | 87.83% | 981.19m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 181.53bn | 995.00 | 32.88 | -- | 19.49 | 2.65 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 182.80bn | 1.65k | 54.39 | -- | 45.87 | 11.18 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Eris Lifesciences Ltd | 22.62bn | 3.80bn | 188.70bn | 3.08k | 49.67 | -- | 30.91 | 8.34 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 194.73bn | 940.00 | 203.14 | -- | 175.57 | 14.03 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Concord Biotech Ltd | 10.38bn | 3.13bn | 198.32bn | 1.38k | 63.34 | -- | 54.05 | 19.11 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 230.31bn | 14.86k | 36.57 | -- | 25.44 | 3.65 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Laurus Labs Ltd | 50.54bn | 1.48bn | 255.64bn | 6.01k | 172.87 | -- | 46.25 | 5.06 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
Natco Pharma Ltd. | 42.21bn | 16.37bn | 257.25bn | 4.02k | 15.72 | -- | 14.10 | 6.09 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Pfizer Ltd | 22.25bn | 6.09bn | 263.45bn | 1.72k | 43.30 | -- | 39.33 | 11.84 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 277.60bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
Gland Pharma Ltd | 58.58bn | 7.22bn | 279.84bn | 4.22k | 38.75 | -- | 25.60 | 4.78 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 280.54bn | 5.31k | 48.84 | -- | 38.18 | 7.81 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Piramal Pharma Ltd | 83.73bn | 277.60m | 292.00bn | 6.72k | 1,050.21 | -- | 37.47 | 3.49 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 305.15bn | 1.05k | 126.76 | -- | 103.12 | 32.65 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Ajanta Pharma Ltd | 43.33bn | 8.54bn | 417.87bn | 7.84k | 49.35 | -- | 42.21 | 9.64 | 67.79 | 67.79 | 343.97 | -- | -- | -- | -- | 5,523,445.00 | -- | 16.61 | -- | 20.47 | 75.01 | 73.22 | 19.71 | 19.31 | -- | -- | -- | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
IPCA Laboratories Ltd | 82.12bn | 5.77bn | 419.89bn | 17.34k | 72.79 | -- | 44.25 | 5.11 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
Holder | Shares | % Held |
---|---|---|
DSP Asset Managers Pvt. Ltd.as of 31 Jul 2024 | 15.27m | 6.00% |
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jul 2024 | 7.04m | 2.77% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 4.01m | 1.57% |
HSBC Asset Management (India) Pvt Ltd.as of 30 Jun 2024 | 2.90m | 1.14% |
Goldman Sachs Asset Management LPas of 31 May 2024 | 2.84m | 1.12% |
Tata Asset Management Pvt Ltd.as of 31 Jul 2024 | 2.60m | 1.02% |
Dimensional Fund Advisors LPas of 04 Jul 2024 | 1.91m | 0.75% |
SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 May 2024 | 1.89m | 0.74% |
BlackRock Fund Advisorsas of 04 Jul 2024 | 1.82m | 0.72% |
Axis Asset Management Co. Ltd.as of 31 Jul 2024 | 1.73m | 0.68% |